MedDataX Logo

Forearm Vascular Relaxation

NCT ID: NCT00182923

Last Updated: 2008-08-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

400 participants

Study Classification

OBSERVATIONAL

Study Start Date

2003-05-31

Study Completion Date

2006-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to learn the effect of inherited differences on forearm blood flow responses to hormones and drugs

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Differences in at least 4 genes are believed to have an important effect on responses to hormones and drugs. For this study, healthy volunteers of normal body weight will be screened to find xxx individuals with the genes of interest. Very small doses of hormones and drugs will be given so that changes in forearm blood flow can be measured, while not causing effects throughout the body. A brachial artery line and venous line will be placed in the study arm so that blood samples may be withdrawn to compare amounts given into the artery and coming out of the vein after circulating through the arm. Forearm blood flow is determined by the rate of swelling of the arm after a blood pressure cuff is inflated (above venous and below arterial blood pressure). The hormones and drugs being studied include angiotensin I, angiotensin II, acetylcholine, sodium nitroprusside, enalaprilat, L-arginine, phenylephrine, endothelin-1, verapamil, and isoproterenol. This procedure will last 4-6 hours. The process will be repeated with the same participant over 2 weeks later.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Blood pressure genetics

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Normal physical status without any medical interventions or agents which would alter the defined status of normal

Exclusion Criteria

* Age less than 21 or greater than 45
* Unable to give informed consent
* BMI (Body Mass Index) less than 18 or greater than 25
* Clinically significant abnormal laboratory values
* Abnormal physical exam
* Abnormal EKG
* Pregnancy
* Smoking or drug usage (illicit or otherwise)
* Post-menopause
* Participation in another clinical trial in the past month
* Chronic Illness
Minimum Eligible Age

21 Years

Maximum Eligible Age

45 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Institute on Aging (NIA)

NIH

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Darrell R. Abernethy, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

National Institute on Aging, Laboratory of Clinical Investigation

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

National Institute on Aging (NIA), Harbor Hospital

Baltimore, Maryland, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Abernethy DR, Laurie N, Andrawis NS. Local angiotensin-converting enzyme inhibition blunts endothelin-1-induced increase in forearm vascular resistance. Clin Pharmacol Ther. 1995 Sep;58(3):328-34. doi: 10.1016/0009-9236(95)90250-3.

Reference Type BACKGROUND
PMID: 7554707 (View on PubMed)

Abernethy DR, Winterbottom LM. Forearm vascular alpha 1-adrenergic blockade by verapamil. Clin Pharmacol Ther. 1990 Jun;47(6):755-9. doi: 10.1038/clpt.1990.104.

Reference Type BACKGROUND
PMID: 2162750 (View on PubMed)

Andrawis NS, Craft N, Abernethy DR. Calcium antagonists block angiotensin II-mediated vasoconstriction in humans: comparison with their effect on phenylephrine-induced vasoconstriction. J Pharmacol Exp Ther. 1992 Jun;261(3):879-84.

Reference Type BACKGROUND
PMID: 1602392 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

AG0038

Identifier Type: -

Identifier Source: org_study_id